Today, the Chief Business Development Off of Neurocrine (NASDAQ: NBIX), Kyle Gano, bought shares of NBIX for $244.8K.
This recent transaction increases Kyle Gano’s holding in the company by 35.9% to a total of $9.11 million. Following Kyle Gano’s last NBIX Buy transaction on March 07, 2018, the stock climbed by 24.3%.
See today’s analyst top recommended stocks >>
Based on Neurocrine’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $96.91 million and GAAP net loss of $5.91 million. In comparison, last year the company earned revenue of $6.34 million and had a GAAP net loss of $59.99 million. The Company has a Price to Book ratio of 27.7100. Currently, Neurocrine has an average volume of 556.1K.
Starting in January 2017, NBIX received 116 Buy ratings in a row. 18 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $128.75, reflecting a -9.9% downside.
The insider sentiment on Neurocrine has been positive according to 68 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.
